{"content":"<li class=\"n-box-item date-title\" data-end=\"1481950799\" data-start=\"1481864400\" data-txt=\"Sunday, December 22, 2019\">Friday, December 16, 2016</li><li class=\"n-box-item sa-box-item\" data-id=\"3231270\" data-ts=\"1481932855\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PUBGY\" target=\"_blank\">PUBGY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231270-publicis-groupe-joins-ad-firms-subpoenaed-doj\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Publicis Groupe joins ad firms subpoenaed by DOJ</a></h4><ul>   <li>France's Publicis Groupe (<a href=\"https://seekingalpha.com/symbol/PUBGY\" title=\"Publicis Groupe S.A. ADR\">OTCQX:PUBGY</a> <font color=\"red\">-0.6%</font>) has acknowledged <a href=\"http://www.wsj.com/articles/omnicom-group-subpoenaed-by-justice-department-in-ad-probe-1481893132\" target=\"_blank\">receiving subpoenas</a> from the U.S. Justice Dept., meaning that a probe into possible price fixing in the $5B video advertising market has touched three ad giants.</li>    <li>Earlier, Omnicom (<a href=\"https://seekingalpha.com/symbol/OMC\" title=\"Omnicom Group Inc.\">OMC</a> <font color=\"red\">-2.1%</font>) <a href=\"https://seekingalpha.com/news/3231073-omnicom-discloses-receiving-doj-subpoenas\" target=\"_blank\">disclosed getting subpoenaed</a>, and Interpublic Group (<a href=\"https://seekingalpha.com/symbol/IPG\" title=\"Interpublic Group of Companies Inc.\">IPG</a> <font color=\"red\">-1.2</font>) was contacted last week for documents.</li>    <li>The DOJ is probing whether ad agencies sent commercial production contracts to in-house units, to the disadvantage of independent companies.</li>    <li>The news comes as ad giants face stronger pressures over the past few years to milk new revenue streams.</li>    <li>FBI agents have interviewed postproduction companies about their experience with the bidding process, <i>The Wall Street Journal</i> reports.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3231270\" data-linked=\"Publicis Groupe joins ad firms subpoenaed by DOJ\" data-tweet=\"$PUBGY $PUBGY $OMC - Publicis Groupe joins ad firms subpoenaed by DOJ https://seekingalpha.com/news/3231270-publicis-groupe-joins-ad-firms-subpoenaed-doj?source=tweet\" data-url=\"https://seekingalpha.com/news/3231270-publicis-groupe-joins-ad-firms-subpoenaed-doj\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231263\" data-ts=\"1481929787\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TI\" target=\"_blank\">TI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231263-telecom-italia-to-spin-off-timvision-to-speed-quad-play-strategy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Telecom Italia to spin off TIMvision to speed quad-play strategy</a></h4><ul>   <li>Telecom Italia (<a href=\"https://seekingalpha.com/symbol/TI\" title=\"Telecom Italia S.P.A.\">TI</a> <font color=\"green\">+1.7%</font>) is starting production of premium content for ultra-broadband, via a <a href=\"http://www.telecomitalia.com/tit/en/archivio/media/comunicati-stampa/telecom-italia/corporate/istituzionale/2016/BoD-1612-FINAL.html\" target=\"_blank\">spin-off of the activities of its TIMvision</a>.</li>    <li>That's designed to accelerate the company's quadruple-play strategy, it says, providing few other details. TIMvision will be the tool to provide the company with exclusive ultra-broadband content \"that will support the uptake of fibre consumption by enlarging the offering of IPTV products and services.\"</li>    <li>A 2017-2019 Strategic Plan set to be unveiled in February will provide more details, TI says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3231263\" data-linked=\"Telecom Italia to spin off TIMvision to speed quad-play strategy\" data-tweet=\"$TI - Telecom Italia to spin off TIMvision to speed quad-play strategy https://seekingalpha.com/news/3231263-telecom-italia-to-spin-off-timvision-to-speed-quad-play-strategy?source=tweet\" data-url=\"https://seekingalpha.com/news/3231263-telecom-italia-to-spin-off-timvision-to-speed-quad-play-strategy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:09 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231255\" data-ts=\"1481927886\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231255-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After-hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5:15 p.m.:</b> <a href='https://seekingalpha.com/symbol/MT' title='ArcelorMittal'>MT</a> <font color='green'>+4.3%</font>. <a href='https://seekingalpha.com/symbol/DCIX' title='Diana Containerships Inc.'>DCIX</a> <font color='green'>+2.2%</font>. <a href='https://seekingalpha.com/symbol/KGC' title='Kinross Gold Corporation'>KGC</a> <font color='green'>+2.0%</font>.</li>     <li><b><b>Top losers</b><b>, as of 5:15 p.m.</b>:</b> <a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a> <font color='red'>-6.9%</font>. <a href='https://seekingalpha.com/symbol/AGNC' title='AGNC Investment Corp.'>AGNC</a> <font color='red'>-1.4%.</font></li> </ul><div class=\"tiny-share-widget\" data-id=\"3231255\" data-linked=\"After-hours Gainers / Losers\" data-tweet=\"$MT $DCIX $KGC - After-hours Gainers / Losers https://seekingalpha.com/news/3231255-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3231255-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231241\" data-ts=\"1481924716\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231241-weekly-etf-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weekly ETF Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/KBWD' title='PowerShares KBW High Dividend Yield Financial Portfolio ETF'>KBWD</a> <font color='green'>+4.5%</font>. <a href='https://seekingalpha.com/symbol/PHO' title='PowerShares Water Resources Portfolio ETF'>PHO</a> <font color='green'>+2.6%</font>. <a href='https://seekingalpha.com/symbol/DBA' title='PowerShares DB Agriculture ETF'>DBA</a> <font color='green'>+1.7%</font>. <a href='https://seekingalpha.com/symbol/IDU' title='iShares U.S. Utilities ETF'>IDU</a> <font color='green'>+1.7%</font>. <a href='https://seekingalpha.com/symbol/IYH' title='iShares U.S. Healthcare ETF'>IYH</a> <font color='green'>+1.7%</font>.</li>     <li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/GDXJ' title='VanEck Vectors Junior Gold Miners ETF'>GDXJ</a> <font color='red'>-12.6%</font>. <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a> <font color='red'>-9.2%</font>. <a href='https://seekingalpha.com/symbol/GDX' title='VanEck Vectors Gold Miners ETF'>GDX</a> <font color='red'>-7.7%</font>. <a href='https://seekingalpha.com/symbol/FXI' title='iShares China Large-Cap ETF'>FXI</a> <font color='red'>-5.3%</font>.</li><li><a href='https://seekingalpha.com/symbol/REMX' title='VanEck Vectors Rare Earth/Strategic Metals ETF'>REMX</a> <font color='red'>-5.2%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3231241\" data-linked=\"Weekly ETF Gainers / Losers\" data-tweet=\"$KBWD $PHO $DBA - Weekly ETF Gainers / Losers https://seekingalpha.com/news/3231241-weekly-etf-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3231241-weekly-etf-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231225\" data-ts=\"1481920153\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHW\" target=\"_blank\">SHW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231225-sherwin-williams-and-valspar-deal-seen-approaching-finish-line\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sherwin-Williams and Valspar deal seen approaching finish line</a></h4><ul>\n<li>Sherwin-Williams (<a href=\"https://seekingalpha.com/symbol/SHW\" title=\"The Sherwin-Williams Company\">SHW</a> <font color=\"green\">+1.7%</font>) could soon win FTC approval for its merger with Valspar (VAL <font color=\"green\">+1.3%</font>), according to <a href=\"http://ctfn.news/limited-divestitures-likely-valsparsherwin-williams-proceeds/\" target=\"_blank\">CTFN</a>.</li>\n<li>The M&amp;A watcher anticipates that only \"limited divestitures\" are likely to result from an agreement with the regulator.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231225\" data-linked=\"Sherwin-Williams and Valspar deal seen approaching finish line\" data-tweet=\"$SHW - Sherwin-Williams and Valspar deal seen approaching finish line https://seekingalpha.com/news/3231225-sherwin-williams-and-valspar-deal-seen-approaching-finish-line?source=tweet\" data-url=\"https://seekingalpha.com/news/3231225-sherwin-williams-and-valspar-deal-seen-approaching-finish-line\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:29 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231219\" data-ts=\"1481919564\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGNC\" target=\"_blank\">AGNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231219-mortgage-reits-recoup-losses\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mortgage REITs recoup some losses</a></h4><ul>\n<li>The iShares FTSE Nareit Mortgage REIT ETF (<a href=\"https://seekingalpha.com/symbol/REM\" title=\"iShares Mortgage Real Estate Capped ETF\">REM</a> <font color=\"green\">+2.1%</font>) is nicely ahead this session, but sill<font color=\"red\"> down more than 3%</font> on the week.</li>\n<li>This week, of course, included the expected Fed rate hike, but the unexpectedly hawkish guidance for 2017. The 10-year Treasury yield has surged all the way to 2.60%, and the two-year yield - at 0.6% just five months ago - flew all the way to 1.26%.</li>\n<li>Also hurting this week was a big decline in book value in November at AGNC Investment (<a href=\"https://seekingalpha.com/symbol/AGNC\" title=\"AGNC Investment Corp.\">AGNC</a> <font color=\"green\">+1.7%</font>) - a bellwether of sorts for agency mREITs.</li>\n<li>Other movers today: Annaly Capital (<a href=\"https://seekingalpha.com/symbol/NLY\" title=\"Annaly Capital Management, Inc.\">NLY</a> <font color=\"green\">+2.8%</font>), Armour (<a href=\"https://seekingalpha.com/symbol/ARR\" title=\"ARMOUR Residential REIT, Inc.\">ARR</a> <font color=\"green\">+1.3%</font>), Two Harbors (<a href=\"https://seekingalpha.com/symbol/TWO\" title=\"Two Harbors Investment Corp.\">TWO</a> <font color=\"green\">+2.1%</font>), CYS Investments (<a href=\"https://seekingalpha.com/symbol/CYS\" title=\"CYS Investments, Inc.\">CYS</a> <font color=\"green\">+3.7%</font>), Invesco (<a href=\"https://seekingalpha.com/symbol/IVR\" title=\"Invesco Mortgage Capital Inc.\">IVR</a> <font color=\"green\">+3.6%</font>), New York Mortgage (<a href=\"https://seekingalpha.com/symbol/NYMT\" title=\"New York Mortgage Trust, Inc.\">NYMT</a> <font color=\"green\">+3.4%</font>), MFA Financial (<a href=\"https://seekingalpha.com/symbol/MFA\" title=\"MFA Financial, Inc.\">MFA</a> <font color=\"green\">+2.1%</font>), Western Asset (<a href=\"https://seekingalpha.com/symbol/WMC\" title=\"Western Asset Mortgage Capital Corporation\">WMC</a> <font color=\"green\">+3.2%</font>), Anworth (<a href=\"https://seekingalpha.com/symbol/ANH\" title=\"Anworth Mortgage Asset Corporation\">ANH</a> <font color=\"green\">+2.9%</font>), Dynex (<a href=\"https://seekingalpha.com/symbol/DX\" title=\"Dynex Capital Inc.\">DX</a> <font color=\"green\">+2.6%</font>).</li>\n<li>ETFs: <a href=\"https://seekingalpha.com/symbol/MORL\" title=\"UBS ETRACS Monthly Pay 2x Leveraged Mortgage REIT ETN\">MORL</a>, <a href=\"https://seekingalpha.com/symbol/MORT\" title=\"VanEck Vectors Mortgage REIT Income ETF\">MORT</a>\n</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3231145-late-week-bounce-reits\" target=\"_blank\">Late-week bounce for REITs</a> (Dec. 16)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231219\" data-linked=\"Mortgage REITs recoup some losses\" data-tweet=\"$AGNC $REM $AGNC - Mortgage REITs recoup some losses https://seekingalpha.com/news/3231219-mortgage-reits-recoup-losses?source=tweet\" data-url=\"https://seekingalpha.com/news/3231219-mortgage-reits-recoup-losses\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231215\" data-ts=\"1481918440\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231215-technology-top-5-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers as of 3:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/JBL' title='Jabil Inc.'>JBL</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/QUIK' title='QuickLogic Corporation'>QUIK</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/CPSH' title='CPS Technologies Corp.'>CPSH</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/OCLR' title='Oclaro, Inc.'>OCLR</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/MRIN' title='Marin Software'>MRIN</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/IZEA' title='IZEA Worldwide, Inc.'>IZEA</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/TZOO' title='Travelzoo Inc'>TZOO</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/SCON' title='Superconductor Technologies Inc.'>SCON</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3231215\" data-linked=\"Technology - Top 5 Gainers / Losers as of 3:00 PM\" data-tweet=\"$JBL $QUIK $CPSH - Technology - Top 5 Gainers / Losers as of 3:00 PM https://seekingalpha.com/news/3231215-technology-top-5-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3231215-technology-top-5-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231214\" data-ts=\"1481917741\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTDOY\" target=\"_blank\">NTDOY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231214-nintendominus-8_5-even-super-mario-run-paces-toward-records\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nintendo -8.5% even as &#39;Super Mario Run&#39; paces toward records</a></h4><ul>   <li>After <a href=\"https://seekingalpha.com/news/3231011-nintendo-minus-3_3-percent-super-mario-run-rolls-success-priced\" target=\"_blank\">selling off yesterday</a> during the launch of its smartphone flagship game <i>Super Mario Run,</i> Nintendo (<a href=\"https://seekingalpha.com/symbol/NTDOY\" title=\"Nintendo Co., Ltd. ADR\">OTCPK:NTDOY</a>) is <font color=\"red\">off another 8.5%</font> in U.S. trading today even amid news that its game is pacing to be the biggest launch in Apple App Store history.</li>    <li>The game was downloaded 2.85M times in its first day, <a href=\"http://www.theverge.com/2016/12/16/13982844/super-mario-run-first-day-downloads\" target=\"_blank\">according to Apptopia</a>, vs. about 900,000 for the first day of <i>Pokémon Go.</i> Sensor Tower <a href=\"http://variety.com/2016/digital/news/super-mario-run-5-million-downloads-1201944212/\" target=\"_blank\">estimates</a> the game has been downloaded more than 5M times, generating more than $5M in revenue and topping download charts in 80 countries.</li>    <li>The revenue key, of course, is how many people have paid and will pay the $9.99 required to unlock all 24 levels of the game. And a three-star average rating shows many users' frustrations with the combination of that price and an easily mastered game.</li>    <li>\n<i>Super Mario Run</i> will wait until 2017 to make its Android OS debut.</li>    <li>Nintendo shares closed <font color=\"red\">down 4.2%</font> in Tokyo today; In U.S./OTC trading, even with today's decline the stock is still <font color=\"green\">up 52%</font> over the past six months.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3231214\" data-linked=\"Nintendo -8.5% even as &#39;Super Mario Run&#39; paces toward records\" data-tweet=\"$NTDOY - Nintendo -8.5% even as &#39;Super Mario Run&#39; paces toward records https://seekingalpha.com/news/3231214-nintendominus-8_5-even-super-mario-run-paces-toward-records?source=tweet\" data-url=\"https://seekingalpha.com/news/3231214-nintendominus-8_5-even-super-mario-run-paces-toward-records\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>46&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231213\" data-ts=\"1481917610\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FRED\" target=\"_blank\">FRED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231213-freds-reportedly-back-in-hunt-for-rite-aid-stores\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fred&#39;s reportedly back in the hunt for Rite Aid stores</a></h4><ul>\n<li>Fred's (NASDAQ:<a href=\"https://seekingalpha.com/symbol/FRED\" title=\"Fred's, Inc.\">FRED</a>) is <font color=\"green\">up 3%</font> amid renewed talk that the company is in the hunt to buy Rite Aid (<a href=\"https://seekingalpha.com/symbol/RAD\" title=\"Rite Aid Corporation\">RAD</a> <font color=\"red\">-0.2%</font>) stores as part of the the Walgreens divestiture.</li>\n<li>\n<a href=\"http://www.dealreporter.com/info/\" target=\"_blank\">DealReporter</a> says Fred's is competing with another strategic buyer and a P/E firm for the Rite Aid stores.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3230318-retail-chains-watch-walgreens-closes-divestiture-deal\" target=\"_blank\">Retail chains on watch as Walgreens closes in on divestiture deal</a> (Dec. 13)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231213\" data-linked=\"Fred&#39;s reportedly back in the hunt for Rite Aid stores\" data-tweet=\"$FRED $FRED $RAD - Fred&#39;s reportedly back in the hunt for Rite Aid stores https://seekingalpha.com/news/3231213-freds-reportedly-back-in-hunt-for-rite-aid-stores?source=tweet\" data-url=\"https://seekingalpha.com/news/3231213-freds-reportedly-back-in-hunt-for-rite-aid-stores\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>42&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231208\" data-ts=\"1481916053\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LGF.A\" target=\"_blank\">LGF.A</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231208-msg-networksminus-1_4-loop-downgrades-to-sell\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MSG Networks -1.4% as Loop downgrades to Sell</a></h4><ul>   <li>A run in MSG Networks (<a href=\"https://seekingalpha.com/symbol/MSGN\" title=\"MSG Networks\">MSGN</a> <font color=\"red\">-1.4%</font>) was largely due to takeover speculation, and investors should look at alternatives, says Loop Capital.</li>    <li>Analyst David Miller downgraded the media company to Sell with a price target of $18, implying another 15% downside from today's depressed pricing.</li>    <li>Investors should <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/16/12/8814949/takeover-speculation-in-msg-networks-is-inefficient-loop\" target=\"_blank\">look instead at positions</a> in its spin-off partner Madison Square Garden (<a href=\"https://seekingalpha.com/symbol/MSG\" title=\"The Madison Square Garden Company\">MSG</a> <font color=\"red\">-0.4%</font>) -- which manages the sports teams and live events -- or in a cheap-looking Lions Gate (<a href=\"https://seekingalpha.com/symbol/LGF.A\" title=\"Lions Gate Entertainment Corp.\">LGF.A</a> <font color=\"red\">-0.8%</font>, <a href=\"https://seekingalpha.com/symbol/LGF.B\" title=\"Lions Gate Entertainment Corp.\">LGF.B</a> <font color=\"green\">+1.9%</font>).</li>    <li>MSGN investors believed that subscriber declines were \"less bad\" than previous ones, whether or not that was accurate, Miller writes. The company said only that subs dropped in the low single digits, but a slower decline than before.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3231208\" data-linked=\"MSG Networks -1.4% as Loop downgrades to Sell\" data-tweet=\"$LGF.A $LGF.A $LGF.B - MSG Networks -1.4% as Loop downgrades to Sell https://seekingalpha.com/news/3231208-msg-networksminus-1_4-loop-downgrades-to-sell?source=tweet\" data-url=\"https://seekingalpha.com/news/3231208-msg-networksminus-1_4-loop-downgrades-to-sell\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231198\" data-ts=\"1481913103\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STON\" target=\"_blank\">STON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231198-stonemor-partners-up-9-after-filing-shelf\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">StoneMor Partners up 9% after filing shelf</a></h4><ul>\n<li>StoneMor (<a href=\"https://seekingalpha.com/symbol/STON\" title=\"StoneMor Partners L.P.\">STON</a> <font color=\"green\">+9.1%</font>) last night <a href=\"https://seekingalpha.com/filing/3326414\" target=\"_blank\">filed a $500M</a> mixed securities shelf offering, and the hope for a capital raise has investors buying.</li>\n<li>The company two days ago held an investor day, and <a href=\"http://s1.q4cdn.com/593583963/files/doc_presentations/2016/STON-Investor-Day-Presentation-FINAL.pdf\" target=\"_blank\">here are the</a> presentation slides.</li>\n<li>\"What Went Wrong,\" is the tile of one section. Listening to outside consultants, the company one year ago slashed its sales staff in an effort to boost productivity - it hasn't paid off. Added to that was a \"lack of vigilance\" on cash cycle management.</li>\n<li>Action steps to correct include rebuilding the sales force while locking in some of those cost cuts.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231198\" data-linked=\"StoneMor Partners up 9% after filing shelf\" data-tweet=\"$STON - StoneMor Partners up 9% after filing shelf https://seekingalpha.com/news/3231198-stonemor-partners-up-9-after-filing-shelf?source=tweet\" data-url=\"https://seekingalpha.com/news/3231198-stonemor-partners-up-9-after-filing-shelf\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231196\" data-ts=\"1481913024\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EGLT\" target=\"_blank\">EGLT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231196-egalets-abuse-deterrent-oxycodone-successful-in-intranasal-abuse-study-shares-up-11\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Egalet&#39;s abuse-deterrent oxycodone successful in intranasal abuse study; shares up 11%</a></h4><ul>\n<li>Egalet (<a href=\"https://seekingalpha.com/symbol/EGLT\" title=\"Egalet Ltd.\">OTC:EGLT</a> <font color=\"green\">+11.1%</font>) perks up on more than double normal volume in response to its announcement of positive results from a Category 3 intranasal human abuse potential (HAP) study of Egalet-002, its abuse-deterrent extended-release oxycodone.</li>\n<li>The study showed a significant decrease in drug liking compared to crushed immediate-release oxycodone.</li>\n<li>Egalet-002 incorporates the company's <a href=\"http://egalet.com/rd/technology-overview/\" target=\"_blank\">Guardian Technology</a> to deter abuse. It utilizes injection molding to create a hard matrix and shell that is designed to be difficult to crush, grind, chew or dissolve. It also turns to gel when exposed to water.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231196\" data-linked=\"Egalet&#39;s abuse-deterrent oxycodone successful in intranasal abuse study; shares up 11%\" data-tweet=\"$EGLT $ZCOR - Egalet&#39;s abuse-deterrent oxycodone successful in intranasal abuse study; shares up 11% https://seekingalpha.com/news/3231196-egalets-abuse-deterrent-oxycodone-successful-in-intranasal-abuse-study-shares-up-11?source=tweet\" data-url=\"https://seekingalpha.com/news/3231196-egalets-abuse-deterrent-oxycodone-successful-in-intranasal-abuse-study-shares-up-11\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231189\" data-ts=\"1481912382\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XBIT\" target=\"_blank\">XBIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231189-xbiotechs-marketing-application-for-xilonix-not-quite-european-regulator-shares-slump-18\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">XBiotech&#39;s marketing application for Xilonix not quite there with European regulator; shares slump 18%</a></h4><ul>\n<li>XBiotech (<a href=\"https://seekingalpha.com/symbol/XBIT\" title=\"Xbiotech\">XBIT</a> <font color=\"red\">-18%</font>) slips on triple normal volume, albeit on turnover of only 350K shares, in response to the company's <a href=\"https://www.sec.gov/Archives/edgar/data/1626878/000117184316013675/f8k_121616.htm\" target=\"_blank\">disclosure </a>that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has objections (requests) related to its Marketing Authorization Application (MAA) seeking approval of Xilonix for the treatment of advanced colorectal cancer, an accelerated review indication.</li>\n<li>According to CHMP's Day 180 List of Outstanding Issues, the committee cites clinical objections related to Xilonix's risk/benefit justification and pharmacokinetics. Quality objections cited relate to the qualification of the cell line used to produce the antibody and scaled down systems used to demonstrate the robustness of the purification process in addition to a clarification of process controls.</li>\n<li>The company believes CHMP's requests are addressable and it intends to submit its responses within 60 days.</li>\n<li>\n<a href=\"http://www.xbiotech.com/clinical/oncology.html\" target=\"_blank\">Xilonix </a>is a True Human monoclonal antibody (IgG1k) that binds to interleukin-1 alpha, thereby blocking the inflammation that supports tumor growth, spread and symptomatic effects of the cancer.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231189\" data-linked=\"XBiotech&#39;s marketing application for Xilonix not quite there with European regulator; shares slump 18%\" data-tweet=\"$XBIT - XBiotech&#39;s marketing application for Xilonix not quite there with European regulator; shares slump 18% https://seekingalpha.com/news/3231189-xbiotechs-marketing-application-for-xilonix-not-quite-european-regulator-shares-slump-18?source=tweet\" data-url=\"https://seekingalpha.com/news/3231189-xbiotechs-marketing-application-for-xilonix-not-quite-european-regulator-shares-slump-18\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231192\" data-ts=\"1481912166\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDCC\" target=\"_blank\">IDCC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231192-b-riley-co-suggests-interdigital-run-too-aggressive\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">B. Riley &amp; Co. suggests InterDigital run too aggressive</a></h4><ul>\n<li>Subsequent yesterday's sharp upward move (shares now <font color=\"green\">+7.8%</font> for the week overall) on a <a href=\"https://seekingalpha.com/news/3230828-interdigital-announces-patent-license-agreement-apple\" target=\"_blank\">patent license arrangement with Apple</a> and <a href=\"https://seekingalpha.com/news/3230831-interdigital-updates-revenue-guidance-q4\" target=\"_blank\">favorable earnings revision</a>, <a href=\"http://blogs.barrons.com/techtraderdaily/2016/12/16/interdigital-stock-jump-on-apple-deal-a-bit-too-much-says-b-riley/\" target=\"_blank\">analyst Eric Wold</a> retains InterDigital (<a href=\"https://seekingalpha.com/symbol/IDCC\" title=\"InterDigital, Inc.\">IDCC</a> <font color=\"red\">-1.7%</font>) at Hold \"given the one-time nature of the Q4 revenue upside and adverse impact to forward revenues.\"</li>\n<li>Retains shares at $80 target (current price $89.40).</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231192\" data-linked=\"B. Riley &amp; Co. suggests InterDigital run too aggressive\" data-tweet=\"$IDCC - B. Riley &amp; Co. suggests InterDigital run too aggressive https://seekingalpha.com/news/3231192-b-riley-co-suggests-interdigital-run-too-aggressive?source=tweet\" data-url=\"https://seekingalpha.com/news/3231192-b-riley-co-suggests-interdigital-run-too-aggressive\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231187\" data-ts=\"1481911565\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JWN\" target=\"_blank\">JWN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231187-sinking-feeling-for-department-store-sector\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sinking feeling for the department store sector</a></h4><ul>          <li>The department store sector is getting roughed up after a pair of analyst notes paint a gloomy picture.</li>\n<li>JPMorgan is out with a harsh assessment on Nordstrom (<a href=\"https://seekingalpha.com/symbol/JWN\" title=\"Nordstrom Inc.\">JWN</a> <font color=\"red\">-8.2%</font>)  (Underweight/$48 PT) and Evercore ISI warns on Trump-led border adjustment taxes for materials sourced outside the U.S.</li>     <li>J.C. Penney (<a href=\"https://seekingalpha.com/symbol/JCP\" title=\"J.C. Penney Company Inc.\">JCP</a> <font color=\"red\">-5.3%</font>), Kohl's (<a href=\"https://seekingalpha.com/symbol/KSS\" title=\"Kohl's Corporation\">KSS</a> <font color=\"red\">-5.1%</font>), Macy's (<a href=\"https://seekingalpha.com/symbol/M\" title=\"Macy's Inc.\">M</a> <font color=\"red\">-4.9%</font>) and Dillard's (<a href=\"https://seekingalpha.com/symbol/DDS\" title=\"Dillard's Inc.\">DDS</a> <font color=\"red\">-1.7%</font>) are all lower.</li>     <li>Previously: <a href=\"https://seekingalpha.com/news/3231063-nordstrom-lower-jpmorgan-loses-faith\" target=\"_blank\">Nordstrom lower after JPMorgan loses faith</a> (Dec. 16)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3231187\" data-linked=\"Sinking feeling for the department store sector\" data-tweet=\"$JWN $JWN $JCP - Sinking feeling for the department store sector https://seekingalpha.com/news/3231187-sinking-feeling-for-department-store-sector?source=tweet\" data-url=\"https://seekingalpha.com/news/3231187-sinking-feeling-for-department-store-sector\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231188\" data-ts=\"1481911529\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231188-financials-top-5-gainers-losers-of-1-05-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:05 PM</a></h4><ul>\n<li>\n<b>Gainers:</b> <a href=\"https://seekingalpha.com/symbol/UBA\" title=\"Urstadt Biddle Properties Inc.\">UBA</a> <font color=\"green\">+8%</font>. <a href=\"https://seekingalpha.com/symbol/LOB\" title=\"Live Oak Bancshares\">LOB</a> <font color=\"green\">+5%</font>. <a href=\"https://seekingalpha.com/symbol/RBPAA\" title=\"Royal Bancshares of Pennsylvania, Inc.\">RBPAA</a> <font color=\"green\">+5%</font>. [[]] <font color=\"green\">+%</font>. [[]] <font color=\"green\">+%</font>.</li>\n<li>\n<b>Losers:</b> <a href=\"https://seekingalpha.com/symbol/IRS\" title=\"IRSA Inversiones Y Representaciones S.A.\">IRS</a> <font color=\"red\">-7%</font>. <a href=\"https://seekingalpha.com/symbol/FAC\" title=\"First Acceptance Corporation\">FAC</a> <font color=\"red\">-6%</font>. <a href=\"https://seekingalpha.com/symbol/CFNL\" title=\"Cardinal Financial Corporation\">CFNL</a> <font color=\"red\">-6%</font>. <a href=\"https://seekingalpha.com/symbol/UBSI\" title=\"United Bankshares, Inc.\">UBSI</a> <font color=\"red\">-6%</font>. <a href=\"https://seekingalpha.com/symbol/PN\" title=\"Patriot National, Inc.\">PN</a> <font color=\"red\">-5%</font>.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231188\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:05 PM\" data-tweet=\"$UBA $LOB $RBPAA - Financials - Top 5 Gainers / Losers as of 1:05 PM https://seekingalpha.com/news/3231188-financials-top-5-gainers-losers-of-1-05-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3231188-financials-top-5-gainers-losers-of-1-05-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231185\" data-ts=\"1481911438\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231185-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/EVOK' title='Evoke Pharma, Inc.'>EVOK</a> <font color='green'>+63%</font>. SGY <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/OPGN' title='OpGen'>OPGN</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/APTO' title='Aptose Biosciences Inc.'>APTO</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/JBL' title='Jabil Inc.'>JBL</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/EGY' title='VAALCO Energy, Inc.'>EGY</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/ORIG' title='Ocean Rig UDW Inc.'>ORIG</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/HZNP' title='Horizon Pharma plc'>HZNP</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/QUIK' title='QuickLogic Corporation'>QUIK</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/EGLT' title='Egalet Ltd.'>OTC:EGLT</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> RXII <font color='red'>-38%</font>. <a href='https://seekingalpha.com/symbol/AGIO' title='Agios Pharmaceuticals, Inc.'>AGIO</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/MLSS' title='Milestone Scientific Inc.'>MLSS</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/CBIO' title='Catalyst Biosciences, Inc.'>CBIO</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/USEG' title='U.S. Energy Corp.'>USEG</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/VCEL' title='Vericel Corporation'>VCEL</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/DCIX' title='Diana Containerships Inc.'>DCIX</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/XBIT' title='Xbiotech'>XBIT</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/ESEA' title='Euroseas Ltd.'>ESEA</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/RKDA' title='Arcadia Biosciences'>RKDA</a> <font color='red'>-11%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3231185\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$EVOK $TALO $OPGN - Midday Gainers / Losers https://seekingalpha.com/news/3231185-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3231185-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231184\" data-ts=\"1481911257\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CACC\" target=\"_blank\">CACC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231184-short-seller-takes-small-bite-out-of-credit-acceptance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Short seller takes small bite out of Credit Acceptance</a></h4><ul>\n<li>The \"squeeze\" higher in Credit Acceptance Corp. (<a href=\"https://seekingalpha.com/symbol/CACC\" title=\"Credit Acceptance Corporation\">CACC</a> <font color=\"red\">-0.5%</font>) over the past few weeks is offering a great opportunity to short a \"red-flag riddled\" stock, <a href=\"https://twitter.com/PresciencePoint\" target=\"_blank\">says Prescience Point Research</a>.</li>\n<li>\"Where's the money,\" asks Prescience Point, noting a $1B gap between dealer holdback paid and what CACC should have paid. The team also spots more than $100M in insider sales this year.</li>\n<li>The price target of $90 compares to the current $208.91.</li>\n<li>CACC slid more than 1% on release of the report a few minutes ago, but now is <font color=\"red\">down just 0.5%</font>.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231184\" data-linked=\"Short seller takes small bite out of Credit Acceptance\" data-tweet=\"$CACC - Short seller takes small bite out of Credit Acceptance https://seekingalpha.com/news/3231184-short-seller-takes-small-bite-out-of-credit-acceptance?source=tweet\" data-url=\"https://seekingalpha.com/news/3231184-short-seller-takes-small-bite-out-of-credit-acceptance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231165\" data-ts=\"1481907634\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GPRO\" target=\"_blank\">GPRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231165-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li>\n<b>Gainers:</b> <a href=\"https://seekingalpha.com/symbol/GPRO\" title=\"GoPro, Inc.\">GPRO</a> <font color=\"green\">+6%</font>.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231165\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$GPRO - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3231165-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3231165-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231154\" data-ts=\"1481905153\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WFT\" target=\"_blank\">WFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231154-weatherford-names-bausch-new-cfo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weatherford names Bausch as its new CFO</a></h4><ul>     <li>Weatherford (<a href=\"https://seekingalpha.com/symbol/WFT\" title=\"Weatherford International Ltd.\">WFT</a> <font color=\"green\">+1.7%</font>) appoints Christoph Bausch as its new CFO, as new CEO Krishna Shivram fills out his management team.</li>     <li>Bausch joined WFT this May as a VP after serving five years as Executive VP and CFO of Norway-based Archer Ltd., and earlier he held various posts at Transocean and Schlumberger.</li>     <li>Also, Frederico Justus is promoted to president of regional operations after serving as VP of the Middle East and Africa region; he joined WFT in 2010.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3231154\" data-linked=\"Weatherford names Bausch as its new CFO\" data-tweet=\"$WFT $WFTIQ - Weatherford names Bausch as its new CFO https://seekingalpha.com/news/3231154-weatherford-names-bausch-new-cfo?source=tweet\" data-url=\"https://seekingalpha.com/news/3231154-weatherford-names-bausch-new-cfo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231152\" data-ts=\"1481905030\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OPGN\" target=\"_blank\">OPGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231152-money-flow-perks-up-in-opgen-and-yet-another-takeover-rumor-shares-up-19\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Money flow perks up in Opgen and (yet another) takeover rumor; shares up 19%</a></h4><ul>\n<li>Nano cap Opgen (<a href=\"https://seekingalpha.com/symbol/OPGN\" title=\"OpGen\">OPGN</a> <font color=\"green\">+19%</font>) is up on more than a 6x surge in volume on apparent message board chatter of the company being an acquisition target. Shares spiked three days ago before making a round trip.</li>\n<li>The company provides molecular testing services via its CLIA-certified laboratory that are used to identify multi-drug-resistant organisms (MDRO). Its lead offering is the Acuitas MDRO Gene Test that directly detects 10 genes unique to MDRO from swab or clinical isolate samples.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231152\" data-linked=\"Money flow perks up in Opgen and (yet another) takeover rumor; shares up 19%\" data-tweet=\"$OPGN - Money flow perks up in Opgen and (yet another) takeover rumor; shares up 19% https://seekingalpha.com/news/3231152-money-flow-perks-up-in-opgen-and-yet-another-takeover-rumor-shares-up-19?source=tweet\" data-url=\"https://seekingalpha.com/news/3231152-money-flow-perks-up-in-opgen-and-yet-another-takeover-rumor-shares-up-19\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231153\" data-ts=\"1481905010\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIVHY\" target=\"_blank\">VIVHY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231153-vivendi-among-bidders-seeking-stake-in-spanish-sports-rights-leader\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vivendi among bidders seeking stake in Spanish sports-rights leader</a></h4><ul>   <li>Vivendi (<a href=\"https://seekingalpha.com/symbol/VIVHY\" title=\"Vivendi SA ADR\">OTCPK:VIVHY</a>) has joined a number of bidders for a <a href=\"http://www.reuters.com/article/us-mediapro-m-a-idUSKBN1451L9?feedType=nl&amp;feedName=innovationNews&amp;utm_source=Sailthru&amp;utm_medium=email&amp;utm_campaign=US%20Deals%20Today%202016-12-16&amp;utm_term=US%20Deals%20Today\" target=\"_blank\">stake in Imagina</a> -- parent to Mediapro and Spain's biggest sports broadcasting rights firm.</li>    <li>Such a move would be a new part of a \"southern strategy\" for Vivendi and its investments in southern Europe, following stakes in Telecom Italia and a battle for the TV business of Italy's Mediaset.</li>    <li>Chinese and U.S. investors make up other bidders in a group of about 10 who hope to take either a 30% or 51% stake in Imagina/Mediapro, Reuters reports. Those include Alibaba's Alisports (<a href=\"https://seekingalpha.com/symbol/BABA\" title=\"Alibaba Group Holding Limited\">BABA</a> <font color=\"green\">+0.7%</font>), China's Citic, Liberty Media (<a href=\"https://seekingalpha.com/symbol/LMCA\" target=\"_blank\">LMCA</a> <font color=\"green\">+1.7%</font>) and Dalian Wanda.</li>    <li>Imagina holds the rights to distribute La Liga soccer championships as well as producing movies and television.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3231153\" data-linked=\"Vivendi among bidders seeking stake in Spanish sports-rights leader\" data-tweet=\"$VIVHY $VIVHY $BABA - Vivendi among bidders seeking stake in Spanish sports-rights leader https://seekingalpha.com/news/3231153-vivendi-among-bidders-seeking-stake-in-spanish-sports-rights-leader?source=tweet\" data-url=\"https://seekingalpha.com/news/3231153-vivendi-among-bidders-seeking-stake-in-spanish-sports-rights-leader\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231151\" data-ts=\"1481904452\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MET\" target=\"_blank\">MET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231151-investors-take-profits-metlife-goes-through-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors take profits as MetLife goes through outlook</a></h4><ul>\n<li>The insurer's hope is for roughly two rate hikes in 2017 and a 10-year Treasury yield about where it is now, and that would boost operating earnings by $45M. A \"stressed\" scenario in which short rates don't move up, and the 10-year Treasury yield returns to 1.5% would cut operating earnings by $50M.</li>\n<li>Met (<a href=\"https://seekingalpha.com/symbol/MET\" title=\"MetLife, Inc.\">MET</a> <font color=\"red\">-3.8%</font>) also is planning for continued increases in rates in 2018 and 2019, and an even bigger boost to earnings.</li>\n<li><a href=\"http://investor.metlife.com/phoenix.zhtml?c=121171&amp;p=irol-presentations\" target=\"_blank\">Presentation slides and webcast replay</a></li>\n<li>Investors are selling the news today after a <font color=\"green\">15% run higher</font> since the election, and a <font color=\"green\">25% move</font> over the past three months.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231151\" data-linked=\"Investors take profits as MetLife goes through outlook\" data-tweet=\"$MET - Investors take profits as MetLife goes through outlook https://seekingalpha.com/news/3231151-investors-take-profits-metlife-goes-through-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3231151-investors-take-profits-metlife-goes-through-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231127\" data-ts=\"1481903986\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231127-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/EVOK' title='Evoke Pharma, Inc.'>EVOK</a> <font color='green'>+59%</font>. <a href='https://seekingalpha.com/symbol/OPGN' title='OpGen'>OPGN</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/HZNP' title='Horizon Pharma plc'>HZNP</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/APTO' title='Aptose Biosciences Inc.'>APTO</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/VSAR-OLD' title='Versartis, Inc.'>VSAR-OLD</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> RXII <font color='red'>-40%</font>. <a href='https://seekingalpha.com/symbol/AGIO' title='Agios Pharmaceuticals, Inc.'>AGIO</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/MLSS' title='Milestone Scientific Inc.'>MLSS</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/CBIO' title='Catalyst Biosciences, Inc.'>CBIO</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/VCEL' title='Vericel Corporation'>VCEL</a> <font color='red'>-14%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3231127\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$EVOK $OPGN $HZNP - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3231127-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3231127-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:59 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231147\" data-ts=\"1481903857\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORCL\" target=\"_blank\">ORCL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231147-oracle-coverage-mostly-positive-despite-4_5-post-earnings-fall-updated\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oracle coverage mostly positive despite 4.5% post-earnings fall [updated]</a></h4><ul>\n<li>\n<a href=\"http://www.streetinsider.com/Analyst+Comments/Drexel+Hamilton+Reiterates+Buy+on+Oracle+%28ORCL%29+Following+2Q+Report/12350463.html\" target=\"_blank\">Drexel Hamilton</a> ($47 target), <a href=\"http://www.streetinsider.com/Analyst+Comments/Wedbush+Raises+Price+Target+on+Oracle+%28ORCL%29+Following+2Q+Report/12350264.html\" target=\"_blank\">Wedbush Securities</a> ($42), <a href=\"http://www.streetinsider.com/Analyst+Comments/Oracle+%28ORCL%29%3A+North+America+At+Low+End+Of+Guidance+But+There+Is+A+Silver+Lining+-+Cowen/12349999.html\" target=\"_blank\">Cowen and Company</a> ($46) and <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/16/12/8814748/oracles-competitive-position-is-improving-cloud-continue\" target=\"_blank\">D.A. Davidson</a> ($52) each reissue associated bullish ratings on Oracle this morning following the company's Q2 disclosure.</li>\n<li>Wunderlich Securities <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/16/12/8814824/oracle-still-needs-to-work-on-its-cloud-opportunity\" target=\"_blank\">analyst Ryan MacDonald</a> comparatively remains sidelined (Hold) with a $43 target, citing FX headwinds and potential for near-term gross margin pressure on heightened initiatives to generate cloud infrastructure growth.</li>\n<li>Oracle (NYSE:<a href=\"https://seekingalpha.com/symbol/ORCL\" title=\"Oracle Corporation\">ORCL</a>) shares are trading to $38.90 on the session decline.</li>\n<li>Yesterday: <a href=\"https://seekingalpha.com/news/3230953-oracle-minus-1_75-percent-q2-print-overall-okay-saas-paas-revenue-81-percent\" target=\"_blank\">Oracle -1.75%; Q2 print overall okay, SaaS, PaaS revenue up 81%</a> / <a href=\"https://seekingalpha.com/article/4030875-oracles-orcl-ceo-mark-hurd-q2-2017-results-earnings-call-transcript\" target=\"_blank\">earnings call transcript</a>\n</li>\n<li>\n<strong>Update</strong>: <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/16/12/8815469/oracles-cloud-business-looks-lumpy-but-strong-going-forw\" target=\"_blank\">J.P. Morgan's Mark Murphy</a> remains Neutral with $42 target on view the company should be able to retain competitiveness long-term, but considers determination over \"whether Oracle will end up on the winning or losing side of cloud computing\" difficult to ascertain.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231147\" data-linked=\"Oracle coverage mostly positive despite 4.5% post-earnings fall [updated]\" data-tweet=\"$ORCL - Oracle coverage mostly positive despite 4.5% post-earnings fall [updated] https://seekingalpha.com/news/3231147-oracle-coverage-mostly-positive-despite-4_5-post-earnings-fall-updated?source=tweet\" data-url=\"https://seekingalpha.com/news/3231147-oracle-coverage-mostly-positive-despite-4_5-post-earnings-fall-updated\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231145\" data-ts=\"1481903578\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UBA\" target=\"_blank\">UBA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231145-late-week-bounce-for-reits\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Late-week bounce for REITs</a></h4><ul>\n<li>REITs were already down on the week prior to the rate hike announcement on Wednesday afternoon, but the Fed's more-hawkish guidance for next year put a further hurt on the sector.</li>\n<li>Buyers are emerging this morning, with <a href=\"https://seekingalpha.com/symbol/VNQ\" title=\"Vanguard Real Estate ETF\">VNQ</a> <font color=\"green\">+1.2%</font> and <a href=\"https://seekingalpha.com/symbol/IYR\" title=\"iShares U.S. Real Estate ETF\">IYR</a><font color=\"green\"> +1%</font> vs. the S&amp;P 500's <font color=\"green\">0.2% advance</font>.</li>\n<li>There <a href=\"https://seekingalpha.com/news/3231138-jpmorgan-reshuffles-reit-ratings\" target=\"_blank\">are a number of</a> sell-side upgrades hitting today, but also some downgrades. Dividend hikes help too, and leading gainers this morning is Urstadt Biddle Properties (<a href=\"https://seekingalpha.com/symbol/UBA\" title=\"Urstadt Biddle Properties Inc.\">UBA</a> <font color=\"green\">+8.5%</font>) after last night's results and dividend hike. CubeSmart (<a href=\"https://seekingalpha.com/symbol/CUBE\" title=\"CubeSmart Common Shares\">CUBE</a> <font color=\"green\">+1.8%</font>) jacked its payout by 28.6%.</li>\n<li>Healthcare Realty Trust (<a href=\"https://seekingalpha.com/symbol/HR\" title=\"Healthcare Realty Trust Inc.\">HR</a> <font color=\"green\">+1.5%</font>) and Healthcare Trust of America (<a href=\"https://seekingalpha.com/symbol/HTA\" title=\"Healthcare Trust of America, Inc.\">HTA</a> <font color=\"green\">+1.8%</font>) were initiated with Buy ratings at Jefferies.</li>\n<li>Gramercy Property Trust (<a href=\"https://seekingalpha.com/symbol/GPT\" title=\"Gramercy Property Trust, Inc.\">GPT</a> <font color=\"green\">+2.9%</font>) announced a big portfolio acquisition.</li>\n<li>Other movers: Realty Income (<a href=\"https://seekingalpha.com/symbol/O\" title=\"Realty Income Corporation\">O</a> <font color=\"green\">+1.8%</font>), National Retail (<a href=\"https://seekingalpha.com/symbol/NNN\" title=\"National Retail Properties, Inc.\">NNN</a> <font color=\"green\">+2.1%</font>), Omega Healthcare (<a href=\"https://seekingalpha.com/symbol/OHI\" title=\"Omega Healthcare Investors, Inc\">OHI</a> <font color=\"green\">+1.8%</font>), Essex Property (<a href=\"https://seekingalpha.com/symbol/ESS\" title=\"Essex Property Trust, Inc.\">ESS</a> <font color=\"green\">+2%</font>), Weingarten Realty (<a href=\"https://seekingalpha.com/symbol/WRI\" title=\"Weingarten Realty Investors\">WRI</a> <font color=\"green\">+1.7%</font>), Life Storage (<a href=\"https://seekingalpha.com/symbol/LSI\" title=\"Life Storage, Inc.\">LSI</a> <font color=\"green\">+1.5%</font>), Government Properties (<a href=\"https://seekingalpha.com/symbol/GOV-OLD\" title=\"Government Properties Income Trust\">GOV-OLD</a> <font color=\"green\">+3.3%</font>), LaSalle Hotel (<a href=\"https://seekingalpha.com/symbol/LHO\" title=\"LaSalle Hotel Properties\">LHO</a> <font color=\"green\">+1.5%</font>), Stag Industrial (<a href=\"https://seekingalpha.com/symbol/STAG\" title=\"STAG Industrial, Inc.\">STAG</a> <font color=\"green\">+1.1%</font>), Eastgroup (<a href=\"https://seekingalpha.com/symbol/EGP\" title=\"EastGroup Properties Inc.\">EGP</a> <font color=\"green\">+1.9%</font>)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231145\" data-linked=\"Late-week bounce for REITs\" data-tweet=\"$UBA $VNQ $IYR - Late-week bounce for REITs https://seekingalpha.com/news/3231145-late-week-bounce-for-reits?source=tweet\" data-url=\"https://seekingalpha.com/news/3231145-late-week-bounce-for-reits\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231133\" data-ts=\"1481901594\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EVOK\" target=\"_blank\">EVOK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231133-evoke-pharma-jumps-38-on-improved-prospects-for-gimoti\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Evoke Pharma jumps 38% on improved prospects for Gimoti</a></h4><ul>\n<li>Thinly traded nano cap Evoke Pharma (<a href=\"https://seekingalpha.com/symbol/EVOK\" title=\"Evoke Pharma, Inc.\">EVOK</a> <font color=\"green\">+37.5%</font>) heads north on a robust 43x surge in volume in response to its announcement of positive guidance from the FDA regarding its marketing application for Gimoti, its nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adult women.</li>\n<li>The agency indicated that no new safety or efficacy data are necessary for an NDA filing. In addition, the regulator agreed that a demonstration of equivalent exposure to the listed drug (Reglan 10 mg tablets) in a pharmacokinetic study in healthy volunteers could be included in the application.</li>\n<li>The company intends to submit the NDA under the accelerated 505(b)(2) pathway which allows the inclusion of data from studies performed by others, good news since the company's Phase 3 study failed to achieve its primary endpoint. Shares plummeted in July when the results were released.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3193711-evoke-pharmas-lead-product-candidate-flunks-late-stage-study-shares-crater-76-percent\" target=\"_blank\">Evoke Pharma's lead product candidate flunks late-stage study; shares crater 76% premarket</a> (July 18)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231133\" data-linked=\"Evoke Pharma jumps 38% on improved prospects for Gimoti\" data-tweet=\"$EVOK - Evoke Pharma jumps 38% on improved prospects for Gimoti https://seekingalpha.com/news/3231133-evoke-pharma-jumps-38-on-improved-prospects-for-gimoti?source=tweet\" data-url=\"https://seekingalpha.com/news/3231133-evoke-pharma-jumps-38-on-improved-prospects-for-gimoti\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231137\" data-ts=\"1481901324\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KSU\" target=\"_blank\">KSU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231137-stifel-analyzes-valuations-in-transportation-sector\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stifel analyzes valuations in the transportation sector</a></h4><ul> <li>Stifel Nicolaus wades deeply into the transportation sector with a series of ratings revisions.</li> <li>In calls tied to attractive valuation, Kansas City Southern (<a href=\"https://seekingalpha.com/symbol/KSU\" title=\"Kansas City Southern\">KSU</a> <font color=\"green\">+0.9%</font>) and Canadian Pacific Railway (<a href=\"https://seekingalpha.com/symbol/CP\" title=\"Canadian Pacific Railway Limited\">CP</a> <font color=\"green\">+0.2%</font>) are both raised to <a href=\"https://www.briefing.com/Investor/PopupPages/ArticlePopup.aspx?ArticleId=UD20161216074607\" target=\"_blank\">Buy</a> from Hold.</li> <li>In a reverse spin on valuation -- Heartland Express (<a href=\"https://seekingalpha.com/symbol/HTLD\" title=\"Heartland Express, Inc.\">HTLD</a> <font color=\"red\">-4.6%</font>), Knight Transportation (<a href=\"https://seekingalpha.com/symbol/KNX\" title=\"Knight-Swift Transportation Holdings Inc.\">KNX</a> <font color=\"red\">-1.7%</font>), Landstar System (<a href=\"https://seekingalpha.com/symbol/LSTR\" title=\"Landstar System, Inc.\">LSTR</a> <font color=\"red\">-1.8%</font>), Celadon Group (<a href=\"https://seekingalpha.com/symbol/CGI\" title=\"Celadon Group, Inc.\">CGI</a> <font color=\"red\">-7%</font>) and Werner Enterprises (<a href=\"https://seekingalpha.com/symbol/WERN\" title=\"Werner Enterprises, Inc.\">WERN</a> <font color=\"red\">-3.1%</font>) are all downgraded to Sell from Hold.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3231137\" data-linked=\"Stifel analyzes valuations in the transportation sector\" data-tweet=\"$KSU $KSU $CP - Stifel analyzes valuations in the transportation sector https://seekingalpha.com/news/3231137-stifel-analyzes-valuations-in-transportation-sector?source=tweet\" data-url=\"https://seekingalpha.com/news/3231137-stifel-analyzes-valuations-in-transportation-sector\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231135\" data-ts=\"1481901147\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231135-ge-upgraded-bernstein-on-positive-effects-of-profitable-growth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GE upgraded at Bernstein on positive effects of more profitable growth</a></h4><ul>     <li>General Electric (<a href=\"https://seekingalpha.com/symbol/GE\" title=\"General Electric\">GE</a> <font color=\"green\">+1.6%</font>) pushes higher in early trading after Bernstein <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/16/12/8814646/ge-feeling-the-positive-effects-of-more-profitable-growt\" target=\"_blank\">upgrades</a> shares to Outperform from Market Perform with a $40 price target, noting a positive transformation in GE's asset portfolio and underperformance by the shares so far this year.</li>     <li>Bernstein's Steven Winoker notes GE's consistently strong earnings growth while its portfolio has changed for the better, and says concerns regarding the risk for the restructuring of Alstom in Europe have been mitigated.</li>     <li>The analyst also sees \u201ca new set of catalysts in the form of potential tax reform, regulatory relief and other factors that should lift GE's businesses beyond 2018.\u201d</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231135\" data-linked=\"GE upgraded at Bernstein on positive effects of more profitable growth\" data-tweet=\"$GE - GE upgraded at Bernstein on positive effects of more profitable growth https://seekingalpha.com/news/3231135-ge-upgraded-bernstein-on-positive-effects-of-profitable-growth?source=tweet\" data-url=\"https://seekingalpha.com/news/3231135-ge-upgraded-bernstein-on-positive-effects-of-profitable-growth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231131\" data-ts=\"1481900608\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VCEL\" target=\"_blank\">VCEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231131-vericel-prices-stock-offering-2_75-shares-ease-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vericel prices stock offering at $2.75; shares ease 10%</a></h4><ul>\n<li>Vericel (<a href=\"https://seekingalpha.com/symbol/VCEL\" title=\"Vericel Corporation\">VCEL</a> <font color=\"red\">-10%</font>) prices its public offering of 6.2M shares of common stock at $2.75. Underwriters over-allotment is an additional 930K shares. Closing date is December 21.</li>\n<li>Net proceeds will fund the commercialization of MACI, expanded promotional activities for Epicel, optimization of manufacturing and general corporate purposes.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231131\" data-linked=\"Vericel prices stock offering at $2.75; shares ease 10%\" data-tweet=\"$VCEL - Vericel prices stock offering at $2.75; shares ease 10% https://seekingalpha.com/news/3231131-vericel-prices-stock-offering-2_75-shares-ease-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3231131-vericel-prices-stock-offering-2_75-shares-ease-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231130\" data-ts=\"1481900312\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CORE\" target=\"_blank\">CORE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231130-core-mark-rallies-strongly-after-wal-mart-signing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Core-Mark rallies strongly after Wal-Mart signing</a></h4><ul> <li>Core-Mark Holding (NASDAQ:<a href=\"https://seekingalpha.com/symbol/CORE\" title=\"Core-Mark Holding Company, Inc.\">CORE</a>) jumps <font color=\"green\">7.14%</font> after the company signs a supplier deal with Wal-Mart.</li> <li>The new arrangement includes a larger distribution of candy products to the world's largest retailer.</li>  <li>Shares of Core-Mark are at their highest level since late August.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3231066-core-mark-inks-new-deal-wal-mart\" target=\"_blank\">Core-Mark inks new deal with Wal-Mart</a> (Dec. 16)</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3231130\" data-linked=\"Core-Mark rallies strongly after Wal-Mart signing\" data-tweet=\"$CORE - Core-Mark rallies strongly after Wal-Mart signing https://seekingalpha.com/news/3231130-core-mark-rallies-strongly-after-wal-mart-signing?source=tweet\" data-url=\"https://seekingalpha.com/news/3231130-core-mark-rallies-strongly-after-wal-mart-signing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231129\" data-ts=\"1481900303\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGCO\" target=\"_blank\">AGCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231129-strong-outlook-boosts-agco-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Strong outlook boosts AGCO higher</a></h4><ul>\n<li>Hosting an analyst meeting today, the company says it sees full-year 2017 adjusted EPS of about $2.50 vs. consensus estimates of just $2.41.</li>\n<li><a href=\"http://investors.agcocorp.com/phoenix.zhtml?c=108419&amp;p=irol-presentations\" target=\"_blank\">Presentation slides</a></li>\n<li>\n<a href=\"https://seekingalpha.com/symbol/AGCO\" title=\"AGCO Corporation\">AGCO</a> <font color=\"green\">+2.25%</font>, and Deere (<a href=\"https://seekingalpha.com/symbol/DE\" title=\"Deere &amp; Company\">DE</a> <font color=\"green\">+0.8%</font>) looks to be benefitting as well.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231129\" data-linked=\"Strong outlook boosts AGCO higher\" data-tweet=\"$AGCO $AGCO $DE - Strong outlook boosts AGCO higher https://seekingalpha.com/news/3231129-strong-outlook-boosts-agco-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3231129-strong-outlook-boosts-agco-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231128\" data-ts=\"1481900211\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231128-micron-technologyplus-2_3-early-target-raised-credit-suisse\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micron Technology +2.3% early, target raised at Credit Suisse</a></h4><ul>\n<li>\n<a href=\"http://thefly.com/landingPageNews.php?id=2478618&amp;headline=MU-Micron-analyst-commentary-\" target=\"_blank\">From $20 to $25 (</a>current price $20.90).</li>\n<li>Analyst John Pitzer moves on DRAM and NAND pricing and higher confidence supply of the former will remain tight through 2017 and the latter, through at least early 2017.</li>\n<li>Outperform rating on Micron Technology (NASDAQ:<a href=\"https://seekingalpha.com/symbol/MU\" title=\"Micron Technology Inc.\">MU</a>) reissued.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231128\" data-linked=\"Micron Technology +2.3% early, target raised at Credit Suisse\" data-tweet=\"$MU - Micron Technology +2.3% early, target raised at Credit Suisse https://seekingalpha.com/news/3231128-micron-technologyplus-2_3-early-target-raised-credit-suisse?source=tweet\" data-url=\"https://seekingalpha.com/news/3231128-micron-technologyplus-2_3-early-target-raised-credit-suisse\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231110\" data-ts=\"1481898767\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WBMD\" target=\"_blank\">WBMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231110-webmd-health-announces-preliminary-results-of-tender-offer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WebMD Health announces preliminary results of its tender offer</a></h4><ul> <li>WebMD Health (NASDAQ:<a href=\"https://seekingalpha.com/symbol/WBMD\" title=\"WebMD Health Corp\">WBMD</a>) announces the preliminary results of its tender offer to purchase up to 2M shares of its common stock at a price of $55.00 per share, for an aggregate purchase price of $110M. Based on the preliminary count ~17.1M shares of common stock were properly tendered and not withdrawn, including: ~6.5M shares that were tendered through notice of guaranteed delivery; and ~0.9M that were tendered as odd lots.</li> <li>WebMD will purchase shares on pro-rata basis. The actual number of shares validly tendered and not withdrawn and the pro-ration factor will be announced following completion of the verification process. Payment for shares purchased is expected to be made on or about December 21. WebMD had ~39.6M shares of common stock outstanding.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3231110\" data-linked=\"WebMD Health announces preliminary results of its tender offer\" data-tweet=\"$WBMD - WebMD Health announces preliminary results of its tender offer https://seekingalpha.com/news/3231110-webmd-health-announces-preliminary-results-of-tender-offer?source=tweet\" data-url=\"https://seekingalpha.com/news/3231110-webmd-health-announces-preliminary-results-of-tender-offer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:32 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231112\" data-ts=\"1481898451\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OPHT\" target=\"_blank\">OPHT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231112-ophthotech-to-cut-many-135-employees-after-fovista-flop-shares-off-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ophthotech to cut as many as 135 employees after Fovista flop; shares off 1% premarket</a></h4><ul>\n<li>In a regulatory filing, Ophthotech (NASDAQ:<a href=\"https://seekingalpha.com/symbol/OPHT\" title=\"Ophthotech Corporation\">OPHT</a>) <a href=\"https://www.sec.gov/Archives/edgar/data/1410939/000110465916162476/a16-23283_18k.htm\" target=\"_blank\">discloses </a>that the recent Fovista failure will necessitate a workforce reduction of 125 - 135 employees. It intends to establish a severance program for affected workers. The cuts should be completed by Q2 2017.</li>\n<li>Its updated business plan will be executed by a workforce of only 20 -30 employees.</li>\n<li>Also, the company has decided to stop treating patients who are in the second 12 months of both its Phase 3 studies (OPH1002 and OPH1003) assessing Fovista and Lucentis in wet AMD and stop treating patients in its Fovista expansion studies.</li>\n<li>Management says it has not had time to make reasonable assessments of the costs related to the above actions.</li>\n<li>Shares are off <font color=\"red\">1%</font> premarket on modest volume.</li>\n<li>\n<strong>Update</strong>: In a <a href=\"https://www.sec.gov/Archives/edgar/data/1410939/000110465917002385/a17-2540_28ka.htm\" target=\"_blank\">regulatory filing</a> submitted on January 17, the company reports that it expects to record $14.4M in pre-tax charges in Q1 and Q2, $13.8M which will be cash expenditures. It adds that its annualized cost savings will be $25M - 30M in Q3.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231112\" data-linked=\"Ophthotech to cut as many as 135 employees after Fovista flop; shares off 1% premarket\" data-tweet=\"$OPHT $ISEE - Ophthotech to cut as many as 135 employees after Fovista flop; shares off 1% premarket https://seekingalpha.com/news/3231112-ophthotech-to-cut-many-135-employees-after-fovista-flop-shares-off-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3231112-ophthotech-to-cut-many-135-employees-after-fovista-flop-shares-off-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231111\" data-ts=\"1481898176\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSL\" target=\"_blank\">TSL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231111-trina-solar-shareholders-approve-going-private-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trina Solar shareholders approve going-private deal</a></h4><ul>     <li>Trina Solar (NYSE:<a href=\"https://seekingalpha.com/symbol/TSL\" title=\"Trina Solar Limited\">TSL</a>) <font color=\"green\">+3.5%</font> premarket after shareholders approve the takeover by a group led by TSL chairman and founder Jifan Gao, to pay $11.60 for each American depositary receipt.</li>     <li>Shares had behaved erratically in recent weeks amid <a href=\"https://www.bloomberg.com/news/articles/2016-11-28/trina-solar-slumps-as-vote-on-1-1-billion-buyout-offer-nears\" target=\"_blank\">speculation</a> that the deal could be in trouble as well as broader pessimism about future prospects for solar companies after Pres.-elect Trump takes office.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231111\" data-linked=\"Trina Solar shareholders approve going-private deal\" data-tweet=\"$TSL - Trina Solar shareholders approve going-private deal https://seekingalpha.com/news/3231111-trina-solar-shareholders-approve-going-private-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3231111-trina-solar-shareholders-approve-going-private-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>62&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231107\" data-ts=\"1481897740\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PHIO\" target=\"_blank\">PHIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231107-rxi-pharma-prices-equity-offering-shares-plummet-41-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RXi Pharma prices equity offering; shares plummet 41% premarket</a></h4><ul>\n<li>RXi Pharmaceuticals (RXII) craters <font color=\"red\">41%</font> premarket on robust volume in response to the pricing of its public equity offering.</li>\n<li>The offering consists of Class A Units, priced at $0.90 and comprised of one share of common stock and one five-year warrant to purchase one share of common at $0.90, and Class B Units, priced at $1,000 each and comprised of one share of Series B Convertible Preferred Stock convertible into 1,111.11 common shares and 1,111.11 warrants.</li>\n<li>A total of 2,131,111 shares of common stock, 8,082 shares of Series B Convertible Preferred stock convertible into 8,980,000 common shares and warrants to purchase 11,111,111 common shares will be issued in the offering.</li>\n<li>Underwriters over-allotment is an additional 1,666,666 common shares and/or warrants to purchase up to 1,666,666 common shares. Closing date is December 21.</li>\n<li>Yesterday's close was $1.38.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231107\" data-linked=\"RXi Pharma prices equity offering; shares plummet 41% premarket\" data-tweet=\"$PHIO - RXi Pharma prices equity offering; shares plummet 41% premarket https://seekingalpha.com/news/3231107-rxi-pharma-prices-equity-offering-shares-plummet-41-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3231107-rxi-pharma-prices-equity-offering-shares-plummet-41-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231104\" data-ts=\"1481897625\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GPOR\" target=\"_blank\">GPOR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231104-gulfport-energyminus-6-after-pricing-stock-note-offerings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gulfport Energy -6% after pricing stock, note offerings</a></h4><ul>\n<li>Gulfport Energy (NASDAQ:<a href=\"https://seekingalpha.com/symbol/GPOR\" title=\"Gulfport Energy Corporation\">GPOR</a>) <font color=\"red\">-5.9%</font> premarket after pricing a 29M-share public offering of common stock at $21.50/share, and pricing at par a $600M offering of 6.375% senior notes due 2025.</li>\n<li>GPOR plans to use the proceeds of the offerings to help fund the previously announced pending <a href=\"https://seekingalpha.com/news/3230716-gulfport-energy-buy-scoop-acreage-1_85b-cash-stock-deal\" target=\"_blank\">acquisition</a> of certain assets of Vitruvian  II Woodford, and for general corporate purposes, which may  include the funding of part of its capital development plans.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231104\" data-linked=\"Gulfport Energy -6% after pricing stock, note offerings\" data-tweet=\"$GPOR - Gulfport Energy -6% after pricing stock, note offerings https://seekingalpha.com/news/3231104-gulfport-energyminus-6-after-pricing-stock-note-offerings?source=tweet\" data-url=\"https://seekingalpha.com/news/3231104-gulfport-energyminus-6-after-pricing-stock-note-offerings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231097\" data-ts=\"1481896793\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMD\" target=\"_blank\">AMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231097-jefferies-increases-to-13-target-on-advanced-micro-devices\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jefferies increases to $13 target on Advanced Micro Devices</a></h4><ul>\n<li>\n<a href=\"http://www.streetinsider.com/Analyst+Comments/AMD+%28AMD%29+PT+Raised+to+%2413+at+Jefferies+on+Increased+Zen+Conviction/12349847.html\" target=\"_blank\">Analyst Mark Lipacis</a> moves from $9 (current price $10.97) prior on what he attributes to the company's undervalued intellectual property and a turnaround, evidenced by this week's <a href=\"https://seekingalpha.com/news/3230407-advanced-micro-devices-introduces-ryzen-processors\" target=\"_blank\">Zen update</a>, he considers underway. Further notes checks observing enthusiastic reception of Zen MPUs within the DT channel and Asia cloud server market.</li>\n<li>Retains shares at Buy and models 2017 and 2018 EPS above consensus, by $0.28 and $0.16 levels, respectively.</li>\n<li>Advanced Micro Devices (NASDAQ:<a href=\"https://seekingalpha.com/symbol/AMD\" title=\"Advanced Micro Devices, Inc.\">AMD</a>) <font color=\"green\">+1%</font> pre-market.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231097\" data-linked=\"Jefferies increases to $13 target on Advanced Micro Devices\" data-tweet=\"$AMD - Jefferies increases to $13 target on Advanced Micro Devices https://seekingalpha.com/news/3231097-jefferies-increases-to-13-target-on-advanced-micro-devices?source=tweet\" data-url=\"https://seekingalpha.com/news/3231097-jefferies-increases-to-13-target-on-advanced-micro-devices\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>66&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231095\" data-ts=\"1481896624\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYL\" target=\"_blank\">MYL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231095-mylan-launches-generic-epipen-wholesale-price-of-300-two-pack-shares-up-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mylan launches generic EpiPen at wholesale price of $300/two-pack; shares up 2% premarket</a></h4><ul>\n<li>Mylan N.V. (NASDAQ:<a href=\"https://seekingalpha.com/symbol/MYL\" title=\"Mylan Inc\">MYL</a>) perks up <font color=\"green\">2%</font> premarket, albeit on only 2,254 shares, in response to its announcement that it has launched an authorized generic EpiPen (epinephrine injection, USP) Auto-Injector at a wholesale acquisition cost (WAC) of $300 per USP two-pack. The company says the price is more than 50% lower than the WAC of the branded version.</li>\n<li>The company has launched an additional patient purchase option at $300 per two-pack to further facilitate access to treatment at the lowest possible price for each patient in addition to a $25 savings card for eligible patients with private insurance.</li>\n<li>The generic product will be in retail pharmacies starting next week.</li>\n<li>Mylan has endured intense criticism over the past several months for its aggressive price increases of the medication used to treat allergic reactions in an emergency setting. Last month, it agreed to pay $465M to settle an investigation by the U.S. Department of Justice related to the misclassification of EpiPen in the Medicaid Drug Rebate Program.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231095\" data-linked=\"Mylan launches generic EpiPen at wholesale price of $300/two-pack; shares up 2% premarket\" data-tweet=\"$MYL - Mylan launches generic EpiPen at wholesale price of $300/two-pack; shares up 2% premarket https://seekingalpha.com/news/3231095-mylan-launches-generic-epipen-wholesale-price-of-300-two-pack-shares-up-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3231095-mylan-launches-generic-epipen-wholesale-price-of-300-two-pack-shares-up-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231093\" data-ts=\"1481895592\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMKTA\" target=\"_blank\">IMKTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231093-on-ingles-markets-fq4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Ingles Markets&#39; FQ4</a></h4><ul>     <li>Ingles Markets (NASDAQ:<a href=\"https://seekingalpha.com/symbol/IMKTA\" title=\"Ingles Markets, Incorporated\">IMKTA</a>) reports comparable-store sales (excl. gasoline sales) rose 1.6% in FQ4.</li>     <li>Gross margin rate improved 80 bps to 24.7%.</li>     <li>Operating margin rate declined 60 bps to 3.3%.</li>     <li>Inventory +1.5% Y/Y to $343.88M.</li>     <li>Store count flat Y/Y to 201.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3231093\" data-linked=\"More on Ingles Markets&#39; FQ4\" data-tweet=\"$IMKTA - More on Ingles Markets&#39; FQ4 https://seekingalpha.com/news/3231093-on-ingles-markets-fq4?source=tweet\" data-url=\"https://seekingalpha.com/news/3231093-on-ingles-markets-fq4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231092\" data-ts=\"1481895438\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LLY\" target=\"_blank\">LLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231092-european-ad-comm-backs-lillys-baricitinib-for-rheumatoid-arthritis-shares-ahead-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">European Ad Comm backs Lilly&#39;s baricitinib for rheumatoid arthritis; shares ahead 2% premarket</a></h4><ul>\n<li>Eli Lilly (NYSE:<a href=\"https://seekingalpha.com/symbol/LLY\" title=\"Eli Lilly and Company\">LLY</a>) is up <font color=\"green\">2%</font> premarket on light volume volume in response to its announcement that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of baricitinib, branded as Olumiant, for the treatment of adult patients with moderate-to-severe active rheumatoid arthritis who have not adequately responded to or are intolerant of one or more disease-modifying anti-rheumatic drugs (DMARDs). Baricitinib can be used as monotherapy or in combination with methotrexate.</li>\n<li>A final decision from the European Commission usually takes ~60 days.</li>\n<li>Regulatory approval will trigger a $65M milestone payment to co-developer Incyte (NASDAQ:<a href=\"https://seekingalpha.com/symbol/INCY\" title=\"Incyte Corporation\">INCY</a>).</li>\n<li>Baricitinib inhibits JAK1 and JAK2, enzymes that play key roles in a range of inflammatory diseases.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231092\" data-linked=\"European Ad Comm backs Lilly&#39;s baricitinib for rheumatoid arthritis; shares ahead 2% premarket\" data-tweet=\"$LLY $LLY $INCY - European Ad Comm backs Lilly&#39;s baricitinib for rheumatoid arthritis; shares ahead 2% premarket https://seekingalpha.com/news/3231092-european-ad-comm-backs-lillys-baricitinib-for-rheumatoid-arthritis-shares-ahead-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3231092-european-ad-comm-backs-lillys-baricitinib-for-rheumatoid-arthritis-shares-ahead-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231085\" data-ts=\"1481894219\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CANF\" target=\"_blank\">CANF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231085-can-fite-to-initiate-mid-stage-study-of-cf102-in-nafld-in-2017-shares-ahead-24-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Can-Fite to initiate mid-stage study of CF102 in NAFLD in 2017; shares ahead 24% premarket</a></h4><ul>\n<li>Based on positive preclinical results, Can-Fite BioPharma (NYSEMKT:<a href=\"https://seekingalpha.com/symbol/CANF\" title=\"Can-Fite BioPharma Ltd.\">CANF</a>) plans to start a Phase 2 study next year assessing namodenoson (CF102) for the treatment of non-alcoholic fatty liver disease (NAFLD), the precursor to non-alcoholic steatohepatitis (NASH).</li>\n<li>New preclinical data showed namodenoson inhibited the growth and proliferation of liver fibrosis cells in a dose-dependent manner, suggesting an anti-fibrotic effect.</li>\n<li>\n<a href=\"http://www.canfite.com/?KPageId=20\" target=\"_blank\">CF102</a> is an orally available small molecule that binds to a protein that is highly expressed in tumor cells called A3 adenosine receptor.</li>\n<li>Shares are up <font color=\"green\">24%</font> premarket on increased volume.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231085\" data-linked=\"Can-Fite to initiate mid-stage study of CF102 in NAFLD in 2017; shares ahead 24% premarket\" data-tweet=\"$CANF - Can-Fite to initiate mid-stage study of CF102 in NAFLD in 2017; shares ahead 24% premarket https://seekingalpha.com/news/3231085-can-fite-to-initiate-mid-stage-study-of-cf102-in-nafld-in-2017-shares-ahead-24-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3231085-can-fite-to-initiate-mid-stage-study-of-cf102-in-nafld-in-2017-shares-ahead-24-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231083\" data-ts=\"1481893854\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBR\" target=\"_blank\">PBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231083-petrobras-signs-5b-deal-for-chinese-financing-oil-supply\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Petrobras signs $5B deal for Chinese financing, oil supply</a></h4><ul>     <li>Petrobras (NYSE:<a href=\"https://seekingalpha.com/symbol/PBR\" title=\"Petrobras - Petroleo Brasileiro S.A.\">PBR</a>) <font color=\"green\">+1.5%</font> premarket following the signing of definitive terms for a <a href=\"http://www.reuters.com/article/us-petrobras-china-idUSKBN14518Y\" target=\"_blank\">$5B, 10-year financing agreement</a> with China Development Bank.</li>     <li>PBR also agrees to sell 100K bbl/day of oil for the 10 years to three Chinese companies, securing a stable stream of revenue and funding for the coming years.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231083\" data-linked=\"Petrobras signs $5B deal for Chinese financing, oil supply\" data-tweet=\"$PBR - Petrobras signs $5B deal for Chinese financing, oil supply https://seekingalpha.com/news/3231083-petrobras-signs-5b-deal-for-chinese-financing-oil-supply?source=tweet\" data-url=\"https://seekingalpha.com/news/3231083-petrobras-signs-5b-deal-for-chinese-financing-oil-supply\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231069\" data-ts=\"1481891285\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IONS\" target=\"_blank\">IONS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231069-ionis-nabs-28m-milestone-from-astrazeneca-for-licensing-kras-targeting-antisense-candidate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ionis nabs $28M milestone from AstraZeneca for licensing KRAS-targeting antisense candidate; shares up 5% premarket</a></h4><ul>\n<li>Ionis Pharmaceuticals (NASDAQ:<a href=\"https://seekingalpha.com/symbol/IONS\" title=\"Ionis Pharmaceuticals, Inc.\">IONS</a>) is <font color=\"green\">5%</font> premarket, albeit on only 699 shares, in response to its announcement that it has earned $28M from AstraZeneca (NYSE:<a href=\"https://seekingalpha.com/symbol/AZN\" title=\"AstraZeneca Group plc\">AZN</a>) triggered by its completion of IND-supporting studies and licensing of IONIS-KRAS-2.5rx (AZD4785), a Generation 2.5 antisense drug that directly targets KRAS, one of the most common genetic mutations in cancer.</li>\n<li>AZN will be responsible for further development as well as commercialization. IONS is eligible for additional milestones valued up to $137M in addition to low double-digit royalties on commercial sales of AZD4785.</li>\n<li>The companies are partnering on the discovery and development of antisense drugs to treat cancer under their December 2012 collaboration agreement.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231069\" data-linked=\"Ionis nabs $28M milestone from AstraZeneca for licensing KRAS-targeting antisense candidate; shares up 5% premarket\" data-tweet=\"$IONS $IONS $AZN - Ionis nabs $28M milestone from AstraZeneca for licensing KRAS-targeting antisense candidate; shares up 5% premarket https://seekingalpha.com/news/3231069-ionis-nabs-28m-milestone-from-astrazeneca-for-licensing-kras-targeting-antisense-candidate?source=tweet\" data-url=\"https://seekingalpha.com/news/3231069-ionis-nabs-28m-milestone-from-astrazeneca-for-licensing-kras-targeting-antisense-candidate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231067\" data-ts=\"1481890677\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HON\" target=\"_blank\">HON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231067-honeywellminus-9-premarket-sees-q4-earnings-low-end-of-previous-forecast\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Honeywell -9% premarket, sees Q4 earnings at low end of previous forecast</a></h4><ul>     <li>Honeywell (NYSE:<a href=\"https://seekingalpha.com/symbol/HON\" title=\"Honeywell International, Inc.\">HON</a>) <font color=\"red\">-8.6%</font> premarket after offering a tepid outlook, reaffirming Q4 EPS guidance of $1.74, at the low end of its earlier forecast of $1.74-$1.78 and below $1.75 analyst consensus estimate.</li>     <li>For FY 2017, HON sees EPS guidance of $6.85-$7.10 vs. $7.08 consensus, on a 1%-2% Y/Y revenue decline; the current sales consensus of  $39.9B <a href=\"http://www.marketwatch.com/story/honeywells-stock-set-for-selloff-after-downbeat-sales-outlook-2016-12-16\" target=\"_blank\">implies 1% growth</a> over the 2016 consensus of $39.5B.</li>     <li>HON also anticipates 2017 organic sales growth of 1%-3%, segment margin expansion of 70-110 bps, and EPS growth of 6%-10%.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3231067\" data-linked=\"Honeywell -9% premarket, sees Q4 earnings at low end of previous forecast\" data-tweet=\"$HON - Honeywell -9% premarket, sees Q4 earnings at low end of previous forecast https://seekingalpha.com/news/3231067-honeywellminus-9-premarket-sees-q4-earnings-low-end-of-previous-forecast?source=tweet\" data-url=\"https://seekingalpha.com/news/3231067-honeywellminus-9-premarket-sees-q4-earnings-low-end-of-previous-forecast\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231063\" data-ts=\"1481890103\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JWN\" target=\"_blank\">JWN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231063-nordstrom-lower-after-jpmorgan-loses-faith\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nordstrom lower after JPMorgan loses faith</a></h4><ul>\n<li>JPMorgan <a href=\"http://www.streetinsider.com/Analyst+PT+Change/JPMorgan+Downgrades+Nordstrom+%28JWN%29+to+Underweight/12349844.html\" target=\"_blank\">downgrades</a> Nordstrom (NYSE:<a href=\"https://seekingalpha.com/symbol/JWN\" title=\"Nordstrom Inc.\">JWN</a>) to Underweight after being stuck at Neutral on the stock.</li>\n<li>The investment firms assigns a price target of $48 to the department store operator.</li>\n<li>Shares of JWN are <font color=\"red\">down 1.56%</font> to $54.42 in premarket action.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231063\" data-linked=\"Nordstrom lower after JPMorgan loses faith\" data-tweet=\"$JWN - Nordstrom lower after JPMorgan loses faith https://seekingalpha.com/news/3231063-nordstrom-lower-after-jpmorgan-loses-faith?source=tweet\" data-url=\"https://seekingalpha.com/news/3231063-nordstrom-lower-after-jpmorgan-loses-faith\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231048\" data-ts=\"1481888731\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VCEL\" target=\"_blank\">VCEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231048-vericel-launches-public-equity-offering-shares-down-16-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vericel launches public equity offering; shares down 16% premarket</a></h4><ul>\n<li>Vericel (NASDAQ:<a href=\"https://seekingalpha.com/symbol/VCEL\" title=\"Vericel Corporation\">VCEL</a>) readies a public offering of common stock. Price, volume and terms have yet to be announced. Shares are off <font color=\"red\">16%</font> premarket on light volume.</li>\n<li>Yesterday's close was $3.50.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231048\" data-linked=\"Vericel launches public equity offering; shares down 16% premarket\" data-tweet=\"$VCEL - Vericel launches public equity offering; shares down 16% premarket https://seekingalpha.com/news/3231048-vericel-launches-public-equity-offering-shares-down-16-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3231048-vericel-launches-public-equity-offering-shares-down-16-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231047\" data-ts=\"1481888539\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HZNP\" target=\"_blank\">HZNP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231047-horizon-pharma-inks-rebate-agreement-express-scripts-shares-ahead-7-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Horizon Pharma inks rebate agreement with Express Scripts; shares ahead 7% premarket</a></h4><ul>\n<li>Horizon Pharma (NASDAQ:<a href=\"https://seekingalpha.com/symbol/HZNP\" title=\"Horizon Pharma plc\">HZNP</a>) <a href=\"https://www.sec.gov/Archives/edgar/data/1492426/000119312516794633/d315384d8k.htm\" target=\"_blank\">closes a rebate agreement</a> with Express Scripts (NASDAQ:<a href=\"https://seekingalpha.com/symbol/ESRX\" title=\"Express Scripts, Inc.\">ESRX</a>) securing formulary status for DUEXIS (ibuprofen and famotidine), VIMOVO (naproxen and esomeprazole magnesium), PENNSAID (diclofenac sodium topical solution) 2% w/w and RAYOS (prednisone) Delayed-Release Tablets. The agreement, effective January 1, 2017, will remove DUEXIS and VIMOVO from ESRX's exclusion list.</li>\n<li>The deal follows earlier rebate agreements with CVS/Caremark and Prime Therapeutics.</li>\n<li>Shares are up <font color=\"green\">7%</font> premarket on increased volume.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231047\" data-linked=\"Horizon Pharma inks rebate agreement with Express Scripts; shares ahead 7% premarket\" data-tweet=\"$HZNP $HZNP $ESRX - Horizon Pharma inks rebate agreement with Express Scripts; shares ahead 7% premarket https://seekingalpha.com/news/3231047-horizon-pharma-inks-rebate-agreement-express-scripts-shares-ahead-7-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3231047-horizon-pharma-inks-rebate-agreement-express-scripts-shares-ahead-7-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231030\" data-ts=\"1481877508\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNY\" target=\"_blank\">SNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231030-bloomberg-sanofi-in-advanced-talks-to-buy-actelion\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bloomberg: Sanofi in advanced talks to buy Actelion</a></h4><ul>     <li>Sanofi (NASDAQ:<a href=\"https://seekingalpha.com/symbol/SNY\" title=\"Sanofi\">SNY</a>), long suspected of coveting Swiss drugmaker Actelion (<a href=\"https://seekingalpha.com/symbol/ALIOF\" title=\"Actelion Ltd.\">OTCPK:ALIOF</a>), is <a href=\"https://www.bloomberg.com/news/articles/2016-12-16/sanofi-said-to-be-in-advanced-talks-to-buy-drugmaker-actelion\" target=\"_blank\">in advanced talks to buy</a> the company and is discussing a takeover price of ~$275/share, Bloomberg reports.</li>     <li>The price may include a contingent value right for Actelion shareholders, which would pay out depending on the future performance of certain pipeline drugs, according to the report.</li>     <li>The potential deal, which would value Actelion at ~$29.6B and follows Johnson &amp; Johnson's reported <a href=\"https://seekingalpha.com/news/3230425-johnson-and-johnson-backs-away-actelion\" target=\"_blank\">withdrawal from the bidding</a>, could come as soon as next week.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3231030\" data-linked=\"Bloomberg: Sanofi in advanced talks to buy Actelion\" data-tweet=\"$SNY $SNY $ALIOF - Bloomberg: Sanofi in advanced talks to buy Actelion https://seekingalpha.com/news/3231030-bloomberg-sanofi-in-advanced-talks-to-buy-actelion?source=tweet\" data-url=\"https://seekingalpha.com/news/3231030-bloomberg-sanofi-in-advanced-talks-to-buy-actelion\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":50,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}